申请人:INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY
OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC
公开号:EP3133080A1
公开(公告)日:2017-02-22
The invention provides compounds of formula I, wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.
本发明提供了式 I 的化合物(其中 R1 和 R2 具有说明书中定义的任何值)及其盐类,以及包含此类化合物的组合物和利用此类化合物的治疗方法。
6-(Het)aryl-7-Deazapurine Ribonucleosides as Novel Potent Cytostatic Agents
A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or lietaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-clilot-o-(7-h ilogeiiztted-)7-deiz ipurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-lialogen tted-)7-de iz tl)tii-iiie ri bon ucleos ides with (het)arylboronic acids. Significant cytostatic effect was detected With a Substantial proportion ofthe prepared compounds. The most potent were 7-H or 7-17 derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabinc. lntr icel]Lll ll'pliosphoi-yl itioil to niono- and triphosphates and the inhibition of total RNA synthesis was denionstrated in preliminary study of metabolism and tinechanistin of action Studies.
The invention provides compounds of formula (I), wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.